SOFT与TEXT III期试验最终结果:绝经前HR阳性早期乳腺癌
SOFT与TEXT试验报告绝经前激素受体阳性早期乳腺癌15年最终结局。SOFT中依西美坦+OFS较他莫昔芬持续降低复发,联合分析显示HER2阴性者 distant recurrence 减少而死亡减少幅度较小,绝对生存获益集中于年轻或高级别等高危亚组。
要点
- SOFT 15年BCFI:E+OFS 78.6%、T+OFS 75.7%、T 72.1%
- HER2阴性联合分析E+OFS较T+OFS降低远处复发(HR 0.75)
- OS绝对获益主要见于年轻或高级别等高危绝经前亚组
核心结论
- 在激素受体阳性、HER2阴性乳腺癌中,辅助依西美坦和/或OFS相较单用他莫昔芬带来的有意义OS获益仅限于高危绝经前亚组。
- 基于他莫昔芬的内分泌治疗在绝经前高级别HER2阴性肿瘤中可能无法获得最佳结局。
研究设计与样本
- SOFT与TEXT为III期随机试验,纳入绝经前激素受体阳性早期乳腺癌患者。
- SOFT意向治疗人群3047例,随机分为5年T、T+OFS或E+OFS。
- TEXT意向治疗人群2660例,随机分为5年T+OFS或E+OFS,化疗可在入组TEXT时与OFS同期进行。
主要发现
- SOFT中E+OFS、T+OFS、T的15年BCFI分别为78.6%、75.7%、72.1%,T+OFS对比T的HR 0.82(95%CI 0.69-0.98,P=0.03)。
- SOFT无化疗队列中OFS在15年时减少乳腺癌事件,而DRFI与OS在各内分泌治疗分组间均保持较高。
- 既往化疗的HER2阴性肿瘤(n=1257)中,SOFT 15年OS率E+OFS为81.0%、T+OFS为77.1%、单用他莫昔芬为76.8%。
- 小于35岁HER2阴性肿瘤(n=241)中,15年OS率E+OFS为82.5%、T+OFS为77.9%、他莫昔芬为68.1%。
- SOFT与TEXT联合分析HER2阴性肿瘤(n=4035)中,E+OFS对比T+OFS降低远处复发(HR 0.75,95%CI 0.63-0.90),死亡减少幅度较小(HR 0.89,95%CI 0.74-1.06)。
关键数值与推荐
- SOFT 15年BCFI:E+OFS 78.6%、T+OFS 75.7%、T 72.1%。
- T+OFS对比T的15年BCFI HR 0.82(95%CI 0.69-0.98,P=0.03)。
- HER2阴性联合分析E+OFS对比T+OFS远处复发HR 0.75(95%CI 0.63-0.90),死亡HR 0.89(95%CI 0.74-1.06)。
临床怎么用
- 绝经前激素受体阳性早期乳腺癌选择辅助内分泌治疗时,应结合年龄、肿瘤级别等风险特征评估OFS与依西美坦的绝对获益。
- 对高危年轻或高级别HER2阴性患者,可考虑含OFS及依西美坦的强化内分泌治疗。
- 单用他莫昔芬可能不是绝经前高级别HER2阴性肿瘤的最佳选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Suppression of Ovarian Function Trial (SOFT) found adding ovarian function suppression (OFS) to tamoxifen (T) reduced breast cancer recurrence, and exemestane (E)+OFS further reduced recurrence. A combined analysis of SOFT and TEXT showed a significant reduction in distant recurrence with E+OFS versus T+OFS. We now report final 15-year outcomes. PATIENTS AND METHODS: Premenopausal women with hormone receptor-positive early breast cancer were enrolled, with 3047 in SOFT and 2660 in TEXT intention-to-treat populations. SOFT randomized to 5 years of T versus T+OFS versus E+OFS. TEXT randomized to 5 years of T+OFS versus E+OFS. Chemotherapy was optional, before SOFT entry with subsequent premenopausal oestradiol or concurrent with OFS in TEXT. Endpoints included disease-free survival, breast cancer-free interval (BCFI), distant recurrence-free interval (DRFI), and overall survival (OS). Additionally, 15-year Kaplan-Meier estimates, hazard ratios (HRs), and 95% confidence intervals (CIs) are reported. RESULTS: In SOFT, escalating endocrine therapy (ET) continued to reduce recurrence with 15-year BCFI of 78.6% for E+OFS, 75.7% for T+OFS, and 72.1% for T (T+OFS versus T: HR 0.82, 95% CI, 0.69-0.98, P = 0.03). In the SOFT no-chemotherapy cohort, OFS reduced breast cancer events at 15 years, while DRFI and OS remained high regardless of ET assignment. After prior chemotherapy for HER2-negative tumors (n = 1257), the 15-year OS rate in SOFT was 81.0% with E+OFS, 77.1% with T+OFS and 76.8% with tamoxifen alone. In women under age 35 years with HER2-negative tumors (n = 241), the 15-year OS rate was 82.5% with E+OFS, 77.9% with T+OFS, and 68.1% with tamoxifen. In combined SOFT and TEXT analysis, among those with HER2-negative tumors (n = 4035), E+OFS versus T+OFS reduced distant recurrence (HR 0.75, 95% CI 0.63-0.90), with a smaller reduction in deaths (HR 0.89, 95% CI 0.74-1.06), with absolute survival benefits largest with high-risk features, particularly young age or high-grade tumors. CONCLUSION: Meaningful OS benefit in hormone receptor-positive, HER2-negative breast cancer from adjuvant exemestane and/or OFS compared with tamoxifen alone is limited to high-risk premenopausal subgroups. Tamoxifen-based ET may not result in optimal outcomes in premenopausal high-grade HER2-negative tumors.
引用
- Francis PA, Pagani O, Fleming GF, et al. Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer. Ann Oncol. 2026. PMID: 42229584. doi:10.1016/j.annonc.2026.05.704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。